Other Research Guide

Endocannabinoids, explained simply with PubMed links

This page translates Endocannabinoids research into plain English: what scientists studied, what kind of evidence exists, where the source links are strong or limited, and which PubMed records support each bucket.

Launch set page

Read Evidence Overview Open Source Table

95research sources

14evidence buckets

PubMedlinked references

What this page is

A plain-English research page about Endocannabinoids. It explains what researchers studied and links the PubMed or DOI sources.

How to use it

Read the overview first. If a sentence matters to you, open the PubMed link or source table below it.

Important limit

This page is education, not medical advice, dosing advice, or a recommendation to use cannabinoids.

Evidence Rows 96

Traceable statements carried into the source table.

Human Evidence 3

Rows where human participants, patients, or clinical evidence are visible.

Mechanisms 30

Biology, target, enzyme, receptor, or pharmacology rows.

Safety / Limits 12

Safety, tolerability, uncertainty, or insufficient-evidence context.

Evidence Overview

Endocannabinoids has research behind it, but the bucket matters.

This page currently indexes 95 research sources across 14 evidence bucket(s). Read it as a map of what researchers have studied, not as a single bottom-line instruction. PMID 12505686

Human evidence 3 evidence rows

Human studies are separated from preclinical and mechanistic evidence so a reader can see where people were actually studied. PMID 12505686

Mechanisms 30 evidence rows

Mechanistic rows explain biological plausibility, receptor activity, enzyme activity, or pharmacology; they do not automatically prove an outcome in people. PMID 12505686

Safety and limits 12 evidence rows

Safety, tolerability, product quality, impairment, interactions, and higher-risk contexts stay visible instead of being treated as footnotes. PMID 12505686

Evidence Buckets

What the Endocannabinoids research is usually about

Jump to source-backed table

CB1

Endocannabinoids appears in rows about CB1 mechanisms. It currently draws from 16 research source(s), and mechanistic evidence should stay separate from human-outcome evidence. PMID 12505686

CB2

Endocannabinoids appears in rows about CB2 mechanisms. It currently draws from 12 research source(s), and mechanistic evidence should stay separate from human-outcome evidence. PMID 12505686

endocannabinoid enzyme activity or metabolic mechanisms

Endocannabinoids appears in rows about endocannabinoid enzyme activity or metabolic mechanisms mechanisms. It currently draws from 12 research source(s), and mechanistic evidence should stay separate from human-outcome evidence. PMID 32203086

Safety, risk, adverse events, and formulation concerns

Endocannabinoids appears in rows studying Safety, risk, adverse events, and formulation concerns. It currently draws from 12 research source(s), so the population, dose, route, and endpoint should be checked before reading across contexts. PMID 28840009

Endocannabinoids and endocannabinoid-like lipids

Endocannabinoids appears in rows studying Endocannabinoids and endocannabinoid-like lipids. It currently draws from 8 research source(s), so the population, dose, route, and endpoint should be checked before reading across contexts. PMID 31325449

GPR18

Endocannabinoids appears in rows about GPR18 mechanisms. It currently draws from 7 research source(s), and mechanistic evidence should stay separate from human-outcome evidence. PMID 34676329

Reader Map

Evidence buckets before the source table

Grouped for readability

Bucket	Plain-English meaning	Evidence posture	Starting source
CB1	Grouped source-backed rows focused on CB1, collapsed into one reader-facing bucket before the full source table.	Mechanistic research summary: insufficient (11), mechanistic or pharmacological (5)	PMID 12505686
CB2	Grouped source-backed rows focused on CB2, collapsed into one reader-facing bucket before the full source table.	Mechanistic research summary: insufficient (6), mechanistic or pharmacological (6)	PMID 12505686
endocannabinoid enzyme activity or metabolic mechanisms	Grouped source-backed rows focused on endocannabinoid enzyme activity or metabolic mechanisms, collapsed into one reader-facing bucket before the full source table.	Developed but mixed human research summary: insufficient (6), mechanistic or pharmacological (3), preclinical (2), preliminary human (1)	PMID 32203086
Safety, risk, adverse events, and formulation concerns	Grouped source-backed rows focused on Safety, risk, adverse events, and formulation concerns, collapsed into one reader-facing bucket before the full source table.	Developed but mixed human research summary: insufficient (10), mechanistic or pharmacological (1), preliminary human (1)	PMID 28840009
Endocannabinoids and endocannabinoid-like lipids	Grouped source-backed rows focused on Endocannabinoids and endocannabinoid-like lipids, collapsed into one reader-facing bucket before the full source table.	Developed but mixed human research summary: insufficient (6), mechanistic or pharmacological (1), preliminary human (1)	PMID 31325449
GPR18	Grouped source-backed rows focused on GPR18, collapsed into one reader-facing bucket before the full source table.	Mechanistic research summary: insufficient (5), mechanistic or pharmacological (2)	PMID 34676329
GPR119	Grouped source-backed rows focused on GPR119, collapsed into one reader-facing bucket before the full source table.	Developed but mixed human research summary: insufficient (4), mechanistic or pharmacological (1), preliminary human (1)	PMID 18426507
receptor, target, or pharmacology mechanisms	Grouped source-backed rows focused on receptor, target, or pharmacology mechanisms, collapsed into one reader-facing bucket before the full source table.	Mechanistic research summary: insufficient (4), mechanistic or pharmacological (2)	PMID 31146657

Safety Reading Notes

Read safety context beside the research guide.

The Endocannabinoids source set includes safety-context rows around Safety, risk, adverse events, and formulation concerns. Public reading should keep these rows beside the benefit-oriented buckets, because product identity, dose, route, population, impairment, interactions, and adverse-event context can change what a study means. PMID 12505686

Developed but mixed human research summary: insufficient (10), mechanistic or pharmacological (1), preliminary human (1)

PubMed For Dummies Article

Endocannabinoids Evidence Review: the long-form source walk-through

Quick read

Endocannabinoids currently has 96 source-backed evidence row(s), so this page should be read as a research guide rather than a single conclusion. PMID 12505686
The evidence classes most visible in the row language are insufficient (59), mechanistic or pharmacological (31), preliminary human (4), and preclinical (2). PMID 31325449
The study-design language most visible in the row language is Narrative or expert review (55), Animal study (22), Cellular or in vitro study (7), and other mapped categories (3). PMID 31146657
The repeated topics are CB1 (16), safety, risk, adverse-event, or formulation-specific concerns (12), endocannabinoid enzyme activity or metabolic mechanisms (12), CB2 (12), and other mapped categories (44), which tells the reader where to start opening PubMed and DOI links. PMID 30670965

Start with the research question

Endocannabinoids is built from 96 source-backed evidence row(s) and 95 research source(s). The current evidence classes read as insufficient (59), mechanistic or pharmacological (31), preliminary human (4), and preclinical (2), and the study-design language most often reads as Narrative or expert review (55), Animal study (22), Cellular or in vitro study (7), and other mapped categories (3). PMID 12505686

The row-level question is not simply whether Endocannabinoids is "good" or "bad." The useful question is what each row studied, what evidence class it received, and whether the source is close to the reader's actual question. The most repeated row topics are CB1 (16), safety, risk, adverse-event, or formulation-specific concerns (12), endocannabinoid enzyme activity or metabolic mechanisms (12), CB2 (12), and other mapped categories (44). PMID 12505686

Human evidence 3 rows

Rows involving human participants, patients, or clinical source language. These rows are closer to everyday reader questions, but still depend on population, dose, route, comparator, and endpoint. PMID 28840009

Preclinical evidence 2 rows

Animal, cellular, or model-based rows. These can explain why a topic is being studied, but they should not be read as human-health instructions. PMID 39206116

Mechanistic evidence 30 rows

Rows about receptors, enzymes, channels, metabolism, binding, signaling, or pharmacology. These explain plausibility without proving a consumer outcome. PMID 33897066

Limits and uncertainty 71 rows

Rows where safety, tolerability, risk, product limits, or insufficient evidence need to stay visible next to the rest of the article. PMID 19575681

The lane labels are not a quality score. They are a reading method: keep human evidence, preclinical evidence, mechanisms, and uncertainty in separate mental boxes before deciding what a source can actually support. PMID 36439263

Where this page has the most source density

The largest bucket surfaced for this page is CB1. That does not automatically mean the topic is settled; it means this is where the current source trail is densest. The next visible bucket is CB2, which gives readers another way to see what the literature repeatedly circles. PMID 12505686

Source density should be read with evidence posture. A bucket can contain many rows and still be limited if the studies are indirect, mixed, preclinical, product-specific, or mostly review-level. The paragraphs below name the buckets directly and keep each explanation connected to a source record. PMID 12505686

Bucket chapters: what the literature is circling

CB1

16 research sources 16 rows (814-862) Mechanistic research summary: insufficient (11), mechanistic or pharmacological (5)

Endocannabinoids appears in rows about CB1 mechanisms. It currently draws from 16 research source(s), and mechanistic evidence should stay separate from human-outcome evidence. PMID 12505686

Read this bucket as mechanism or pharmacology context. Mechanisms can make the biology easier to understand, but they are not the same thing as a demonstrated effect in people. PMID 12505686

Evidence row 814
Endocannabinoids modulates CB1; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: CB1 receptor pharmacology, ligand binding, or s... PMID 12505686
Evidence row 862
Endocannabinoids modulates CB1; evidence class: insufficient (population or model: Animal model mentioned; study design: Narrative or expert review; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain, cognition, or... PMID 16596773

CB2

12 research sources 12 rows (868-917) Mechanistic research summary: insufficient (6), mechanistic or pharmacological (6)

Endocannabinoids appears in rows about CB2 mechanisms. It currently draws from 12 research source(s), and mechanistic evidence should stay separate from human-outcome evidence. PMID 12505686

Read this bucket as mechanism or pharmacology context. Mechanisms can make the biology easier to understand, but they are not the same thing as a demonstrated effect in people. PMID 12505686

Evidence row 868
Endocannabinoids modulates CB2; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: CB2 receptor pharmacology, ligand binding, sele... PMID 12505686
Evidence row 917
Endocannabinoids modulates CB2; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: CB2 immune, inflammatory, microglial, neuro... PMID 24877594

endocannabinoid enzyme activity or metabolic mechanisms

12 research sources 12 rows (300-314) Developed but mixed human research summary: insufficient (6), mechanistic or pharmacological (3), preclinical (2), preliminary human (1)

Read this bucket as closer to a real-world question, then check the study population, dose, product, comparator, and endpoint before generalizing beyond the source. PMID 32203086

Evidence row 300
Endocannabinoids modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms). PMID 32203086
Evidence row 314
Endocannabinoids modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: preliminary human (population or model: Human participants or patients mentioned; outcome measure: endocannabinoid enzyme activ... PMID 22969151

Safety, risk, adverse events, and formulation concerns

12 research sources 12 rows (222-347) Developed but mixed human research summary: insufficient (10), mechanistic or pharmacological (1), preliminary human (1)

Read this bucket as safety context first. It belongs beside any benefit-oriented rows because risk, route, dose, product quality, co-exposures, and population can change what a source means. PMID 28840009

Evidence row 222
Endocannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review;... PMID 28840009
Evidence row 347
Endocannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measur... PMID 31350927

Endocannabinoids and endocannabinoid-like lipids

8 research sources 8 rows (202-299) Developed but mixed human research summary: insufficient (6), mechanistic or pharmacological (1), preliminary human (1)

Read this bucket as closer to a real-world question, then check the study population, dose, product, comparator, and endpoint before generalizing beyond the source. PMID 31325449

Evidence row 202
Endocannabinoids studied for Endocannabinoids and endocannabinoid-like lipids research topics; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design... PMID 31325449
Evidence row 299
Endocannabinoids studied for Endocannabinoids and endocannabinoid-like lipids research topics; evidence class: preliminary human (population or model: Human participants or patients mentioned; outcome measure: Endo... PMID 41035123

GPR18

7 research sources 7 rows (947-961) Mechanistic research summary: insufficient (5), mechanistic or pharmacological (2)

Endocannabinoids appears in rows about GPR18 mechanisms. It currently draws from 7 research source(s), and mechanistic evidence should stay separate from human-outcome evidence. PMID 34676329

Read this bucket as mechanism or pharmacology context. Mechanisms can make the biology easier to understand, but they are not the same thing as a demonstrated effect in people. PMID 34676329

Evidence row 947
Endocannabinoids modulates GPR18; evidence class: insufficient (study design: Narrative or expert review; outcome measure: GPR18 receptor activity, binding, signaling, or pharmacology). PMID 34676329
Evidence row 961
Endocannabinoids modulates GPR18; evidence class: insufficient (population or model: Animal model mentioned; study design: Narrative or expert review; outcome measure: GPR18 receptor activity, binding, signaling, or pharmacology). PMID 18187165

GPR119

6 research sources 6 rows (963-970) Developed but mixed human research summary: insufficient (4), mechanistic or pharmacological (1), preliminary human (1)

Endocannabinoids appears in rows about GPR119 mechanisms. It currently draws from 6 research source(s), and mechanistic evidence should stay separate from human-outcome evidence. PMID 18426507

Read this bucket as closer to a real-world question, then check the study population, dose, product, comparator, and endpoint before generalizing beyond the source. PMID 18426507

Evidence row 963
Endocannabinoids modulates GPR119; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: GPR119 receptor activity, binding, signa... PMID 18426507
Evidence row 970
Endocannabinoids modulates GPR119; evidence class: insufficient (study design: Narrative or expert review; outcome measure: GPR119 receptor activity, binding, signaling, metabolic physiology, or pharmacology). PMID 30537148

receptor, target, or pharmacology mechanisms

6 research sources 6 rows (209-265) Mechanistic research summary: insufficient (4), mechanistic or pharmacological (2)

Endocannabinoids appears in rows about receptor, target, or pharmacology mechanisms mechanisms. It currently draws from 6 research source(s), and mechanistic evidence should stay separate from human-outcome evidence. PMID 31146657

Read this bucket as mechanism or pharmacology context. Mechanisms can make the biology easier to understand, but they are not the same thing as a demonstrated effect in people. PMID 31146657

Evidence row 209
Endocannabinoids modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: re... PMID 31146657
Evidence row 265
Endocannabinoids modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: re... PMID 28861502

Human evidence, mechanisms, and safety are different lanes

This page currently separates human evidence (3 row(s)), mechanistic evidence (30 row(s)), and safety/tolerability context (12 row(s)). That separation is the heart of the site. Mechanistic evidence can make a topic biologically interesting, but it should not silently become a human outcome. PMID 12505686

Human evidence still depends on population, dose, route, duration, product identity, and endpoint. Safety rows belong in the same reading path as benefit-oriented rows because formulation, co-exposures, prescription medications, impairment context, and higher-risk populations can change how close a source is to a reader's question. PMID 12505686

What this does and does not mean

It means the page has a traceable source trail. It does not mean every bucket has the same clinical strength. PMID 18755158
It means mechanisms, animal models, human studies, safety rows, and insufficient-evidence rows are being kept visible as separate evidence types. PMID 16107637
It does not turn a preclinical mechanism into a consumer recommendation, and it does not treat one product, dose, route, or population as interchangeable with another. PMID 28861502

How to use the source table

The source-backed evidence table below is the audit trail. Each row keeps a public sentence connected to a source record when a PubMed ID or DOI is available. If a sentence feels important, the reader should be able to click through, inspect the study type, and decide whether the source is close to the question they care about. PMID 12505686

This is why the public page is intentionally layered. The top gives the reader a fast orientation. The bucket table groups repeated rows into readable topics. The article body explains the buckets using the actual evidence-row language. The source notes below walk through every evidence row before the source table repeats the technical trace. PMID 12505686

Source-reading checklist for Endocannabinoids

Open the linked PubMed or DOI record. PMID 40016352
Check whether the source studied humans, animals, cells, chemistry, pharmacology, product testing, or a review of prior literature. PMID 34607960
Compare the source product, dose, route, population, and endpoint to the question being asked. PMID 37962860
Look for safety, tolerability, drug-interaction, impairment, pregnancy, pediatric, psychiatric, cardiovascular, and product-quality context before treating the bucket as settled. PMID 28826539
Return to the evidence table when the article summary sounds too broad; the row is the audit unit. PMID 9831287

Source Notes

Endocannabinoids source-by-source reading notes

These notes pull every evidence row on this page into the readable article body before the source table repeats the audit trail. Each note keeps the row language beside the PubMed or DOI link when available.

Evidence row 202
Endocannabinoids studied for Endocannabinoids and endocannabinoid-like lipids research topics; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: Endocannabinoids and endocannabinoid-like lipids research topics). PMID 31325449
Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Endocannabinoids and endocannabinoid-like compounds modulate hypoxia-induced permeability in CaCo-2 cells via CB1, TRPV1, and PPARα.
Evidence row 209
Endocannabinoids modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: receptor, target, or pharmacology mechanisms). PMID 31146657
Evidence class: insufficient; Study design: Narrative or expert review. Source: Potential metabolic and behavioural roles of the putative endocannabinoid receptors GPR18, GPR55 and GPR119 in feeding.
Evidence row 210
Endocannabinoids modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: receptor, target, or pharmacology mechanisms). PMID 30670965
Evidence class: insufficient; Study design: Narrative or expert review. Source: Some Prospective Alternatives for Treating Pain: The Endocannabinoid System and Its Putative Receptors GPR18 and GPR55.
Evidence row 222
Endocannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: safety, risk, adverse-event, or formulation-specific concerns). PMID 28840009
Evidence class: insufficient; Study design: Narrative or expert review. Source: Role of cannabis in cardiovascular disorders.
Evidence row 237
Endocannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient (study design: Narrative or expert review; outcome measure: safety, risk, adverse-event, or formulation-specific concerns). PMID 39206116
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoids and monoaminergic system: implications for learning and memory.
Evidence row 238
Endocannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: preliminary human (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Human clinical study; outcome measure: safety, risk, adverse-event, or formulation-specific concerns). PMID 33897066
Evidence class: preliminary human; Study design: Human clinical study. Source: Adverse Effects of Recreational and Medical Cannabis.
Evidence row 241
Endocannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient (study design: Narrative or expert review; outcome measure: safety, risk, adverse-event, or formulation-specific concerns). PMID 19575681
Evidence class: insufficient; Study design: Narrative or expert review. Source: Endocannabinoid signaling and long-term synaptic plasticity.
Evidence row 258
Endocannabinoids modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient (study design: Systematic review; outcome measure: receptor, target, or pharmacology mechanisms). PMID 36439263
Evidence class: insufficient; Study design: Systematic review. Source: Cys-loop receptors on cannabinoids: All high?
Evidence row 260
Endocannabinoids modulates receptor, target, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: receptor, target, or pharmacology mechanisms). PMID 18755158
Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Subunit-specific modulation of glycine receptors by cannabinoids and N-arachidonyl-glycine.
Evidence row 262
Endocannabinoids modulates receptor, target, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: receptor, target, or pharmacology mechanisms). PMID 16107637
Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Glycine receptors in CNS neurons as a target for nonretrograde action of cannabinoids.
Evidence row 265
Endocannabinoids modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: receptor, target, or pharmacology mechanisms). PMID 28861502
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoids in Parkinson's Disease.
Evidence row 268
Endocannabinoids studied for Cannabinoids and immune modulation research outcomes; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: Cannabinoids and immune modulation research outcomes). PMID 40016352
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Astrocytic cannabinoid receptor 1 promotes resilience by dampening stress-induced blood-brain barrier alterations.
Evidence row 271
Endocannabinoids studied for Cannabinoids and immune modulation research outcomes; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: Cannabinoids and immune modulation research outcomes). PMID 34607960
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Phospholipase Cγ2 regulates endocannabinoid and eicosanoid networks in innate immune cells.
Evidence row 272
Endocannabinoids studied for Cannabinoids and immune modulation research outcomes; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: Cannabinoids and immune modulation research outcomes). PMID 37962860
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Impact of Chronic Moderate Exercise on Immune Cells and Cytokine Levels in Rats: Focus on the Endocannabinergic Pathway.
Evidence row 290
Endocannabinoids studied for Endocannabinoids and endocannabinoid-like lipids research topics; evidence class: insufficient (study design: Narrative or expert review; outcome measure: Endocannabinoids and endocannabinoid-like lipids research topics). PMID 28826539
Evidence class: insufficient; Study design: Narrative or expert review. Source: Endocannabinoid Turnover.
Evidence row 291
Endocannabinoids studied for Endocannabinoids and endocannabinoid-like lipids research topics; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: Endocannabinoids and endocannabinoid-like lipids research topics). PMID 9831287
Evidence class: insufficient; Study design: Narrative or expert review. Source: Endocannabinoids.
Evidence row 295
Endocannabinoids studied for Endocannabinoids and endocannabinoid-like lipids research topics; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: Endocannabinoids and endocannabinoid-like lipids research topics). PMID 24677570
Evidence class: insufficient; Study design: Narrative or expert review. Source: Classical endocannabinoid-like compounds and their regulation by nutrients.
Evidence row 296
Endocannabinoids studied for Endocannabinoids and endocannabinoid-like lipids research topics; evidence class: insufficient (outcome measure: Endocannabinoids and endocannabinoid-like lipids research topics). PMID 38909454
Evidence class: insufficient. Source: Effects of fermentation and alkalisation on the formation of endocannabinoid-like compounds in olives.
Evidence row 297
Endocannabinoids studied for Endocannabinoids and endocannabinoid-like lipids research topics; evidence class: insufficient (outcome measure: Endocannabinoids and endocannabinoid-like lipids research topics). PMID 38296973
Evidence class: insufficient. Source: Endocannabinoids, endocannabinoid-like compounds and cortisone in head hair of health care workers as markers of stress and resilience during the early COVID-19 pandemic.
Evidence row 298
Endocannabinoids studied for Endocannabinoids and endocannabinoid-like lipids research topics; evidence class: insufficient (outcome measure: Endocannabinoids and endocannabinoid-like lipids research topics). PMID 34115519
Evidence class: insufficient. Source: Roles of Endocannabinoids and Endocannabinoid-Like Molecules in Energy Homeostasis and Metabolic Regulation: A Nutritional Perspective.
Evidence row 299
Endocannabinoids studied for Endocannabinoids and endocannabinoid-like lipids research topics; evidence class: preliminary human (population or model: Human participants or patients mentioned; outcome measure: Endocannabinoids and endocannabinoid-like lipids research topics). PMID 41035123
Evidence class: preliminary human. Source: Liquid Chromatography-Tandem Mass Spectrometry Method for Simultaneous Quantification of Four Endocannabinoids and Endocannabinoid-Like Substances in Plasma: Application in an HIV-Hepatitis C Virus Coinfected Population.
Evidence row 300
Endocannabinoids modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms). PMID 32203086
Evidence class: insufficient; Study design: Narrative or expert review. Source: Potential application of endocannabinoid system agents in neuropsychiatric and neurodegenerative diseases-focusing on FAAH/MAGL inhibitors.
Evidence row 301
Endocannabinoids modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms). PMID 40269679
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Inhibition of endocannabinoid hydrolases MAGL, FAAH and ABHD6 by AKU-005 reduces ex vivo cortical spreading depression.
Evidence row 302
Endocannabinoids modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms). PMID 34217798
Evidence class: insufficient; Study design: Narrative or expert review. Source: The role of endocannabinoid pathway in the neuropathology of Alzheimer's disease: Can the inhibitors of MAGL and FAAH prove to be potential therapeutic targets against the cognitive impairment associated with Alzheimer's disease?
Evidence row 304
Endocannabinoids modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms). PMID 34959715
Evidence class: insufficient; Study design: Narrative or expert review. Source: Potential of Fatty Acid Amide Hydrolase (FAAH), Monoacylglycerol Lipase (MAGL), and Diacylglycerol Lipase (DAGL) Enzymes as Targets for Obesity Treatment: A Narrative Review.
Evidence row 305
Endocannabinoids modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms). PMID 41092478
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Inhibition of endocannabinoid synthesis enzymes DAGL and NAPE-PLD transiently lowers body weight and alters glucose homeostasis during a high-fat diet challenge in mice.
Evidence row 306
Endocannabinoids modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: preclinical (population or model: Animal model mentioned; study design: Animal study; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms). PMID 24346263
Evidence class: preclinical; Study design: Animal study. Source: Subcellular localization of NAPE-PLD and DAGL-α in the ventromedial nucleus of the hypothalamus by a preembedding immunogold method.
Evidence row 307
Endocannabinoids modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms). PMID 39245706
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Microglial morphological/inflammatory phenotypes and endocannabinoid signaling in a preclinical model of periodontitis and depression.
Evidence row 308
Endocannabinoids modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms). PMID 17346227
Evidence class: insufficient; Study design: Narrative or expert review. Source: Critical enzymes involved in endocannabinoid metabolism.
Evidence row 310
Endocannabinoids modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms). PMID 30564946
Evidence class: insufficient; Study design: Narrative or expert review. Source: Structural properties and role of the endocannabinoid lipases ABHD6 and ABHD12 in lipid signalling and disease.
Evidence row 312
Endocannabinoids modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms). PMID 21418147
Evidence class: insufficient; Study design: Narrative or expert review. Source: The serine hydrolases MAGL, ABHD6 and ABHD12 as guardians of 2-arachidonoylglycerol signalling through cannabinoid receptors.
Evidence row 313
Endocannabinoids modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: preclinical (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms). PMID 30075103
Evidence class: preclinical; Study design: Animal study. Source: Deregulation of the endocannabinoid system and therapeutic potential of ABHD6 blockade in the cuprizone model of demyelination.
Evidence row 314
Endocannabinoids modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: preliminary human (population or model: Human participants or patients mentioned; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms). PMID 22969151
Evidence class: preliminary human. Source: Biochemical and pharmacological characterization of human α/β-hydrolase domain containing 6 (ABHD6) and 12 (ABHD12).
Evidence row 319
Endocannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: safety, risk, adverse-event, or formulation-specific concerns). PMID 18426501
Evidence class: insufficient; Study design: Narrative or expert review. Source: Endocannabinoids, blood pressure and the human heart.
Evidence row 336
Endocannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient (study design: Narrative or expert review; outcome measure: safety, risk, adverse-event, or formulation-specific concerns). PMID 31599175
Evidence class: insufficient; Study design: Narrative or expert review. Source: The potential role of cannabinoids in dermatology.
Evidence row 339
Endocannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: safety, risk, adverse-event, or formulation-specific concerns). PMID 38003712
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoids and Their Receptors in Skin Diseases.
Evidence row 343
Endocannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient (study design: Narrative or expert review; outcome measure: safety, risk, adverse-event, or formulation-specific concerns). PMID 33909195
Evidence class: insufficient; Study design: Narrative or expert review. Source: Endocannabinoid system and its modulation of brain, gut, joint and skin inflammation.
Evidence row 344
Endocannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient (study design: Narrative or expert review; outcome measure: safety, risk, adverse-event, or formulation-specific concerns). PMID 30138623
Evidence class: insufficient; Study design: Narrative or expert review. Source: The endocannabinoid system of the skin. A potential approach for the treatment of skin disorders.
Evidence row 345
Endocannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: safety, risk, adverse-event, or formulation-specific concerns). PMID 36439142
Evidence class: insufficient; Study design: Narrative or expert review. Source: Sebaceous immunobiology - skin homeostasis, pathophysiology, coordination of innate immunity and inflammatory response and disease associations.
Evidence row 346
Endocannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: safety, risk, adverse-event, or formulation-specific concerns). PMID 19608284
Evidence class: insufficient; Study design: Narrative or expert review. Source: The endocannabinoid system of the skin in health and disease: novel perspectives and therapeutic opportunities.
Evidence row 347
Endocannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: safety, risk, adverse-event, or formulation-specific concerns). PMID 31350927
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Modulators of the endocannabinoid system influence skin barrier repair, epidermal proliferation, differentiation and inflammation in a mouse model.
Evidence row 814
Endocannabinoids modulates CB1; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms). PMID 12505686
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinergic ligands.
Evidence row 815
Endocannabinoids modulates CB1; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms). PMID 27245890
Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Assay of CB1 Receptor Binding.
Evidence row 818
Endocannabinoids modulates CB1; evidence class: insufficient (study design: Narrative or expert review; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms). PMID 27879006
Evidence class: insufficient; Study design: Narrative or expert review. Source: Allosteric Modulation: An Alternate Approach Targeting the Cannabinoid CB1 Receptor.
Evidence row 827
Endocannabinoids modulates CB1; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms). PMID 26408156
Evidence class: insufficient; Study design: Narrative or expert review. Source: Endocannabinoids and Their Pharmacological Actions.
Evidence row 833
Endocannabinoids modulates CB1; evidence class: insufficient (study design: Narrative or expert review; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms). PMID 39828030
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoid receptor 1 ligands: Biased signaling mechanisms driving functionally selective drug discovery.
Evidence row 836
Endocannabinoids modulates CB1; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms). PMID 40521518
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Synthesis and Pharmacological Characterization of a Novel Cannabinoid Receptor 1 Antagonist.
Evidence row 842
Endocannabinoids modulates CB1; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain, cognition, or synaptic mechanisms). PMID 34050525
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoid-based therapy as a future for joint degeneration. Focus on the role of CB2 receptor in the arthritis progression and pain: an updated review.
Evidence row 846
Endocannabinoids modulates CB1; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain, cognition, or synaptic mechanisms). PMID 16570099
Evidence class: insufficient; Study design: Narrative or expert review. Source: The pharmacology of cannabinoid receptors and their ligands: an overview.
Evidence row 847
Endocannabinoids modulates CB1; evidence class: insufficient (study design: Narrative or expert review; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain, cognition, or synaptic mechanisms). PMID 19939187
Evidence class: insufficient; Study design: Narrative or expert review. Source: Latest advances in cannabinoid receptor agonists.
Evidence row 849
Endocannabinoids modulates CB1; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain, cognition, or synaptic mechanisms). PMID 31461639
Evidence class: insufficient; Study design: Narrative or expert review. Source: Therapeutic potential of cannabinoid receptor 2 in the treatment of diabetes mellitus and its complications.
Evidence row 850
Endocannabinoids modulates CB1; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain, cognition, or synaptic mechanisms). PMID 15550444
Evidence class: insufficient; Study design: Narrative or expert review. Source: The endocannabinoid system: physiology and pharmacology.
Evidence row 853
Endocannabinoids modulates CB1; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain, cognition, or synaptic mechanisms). PMID 40855505
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Restoration of CB1 receptor function in hippocampal GABAergic neurons rescues memory deficits in Huntington's disease models.
Evidence row 855
Endocannabinoids modulates CB1; evidence class: insufficient (study design: Narrative or expert review; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain, cognition, or synaptic mechanisms). PMID 25967266
Evidence class: insufficient; Study design: Narrative or expert review. Source: Astroglial type-1 cannabinoid receptor (CB1): A new player in the tripartite synapse.
Evidence row 857
Endocannabinoids modulates CB1; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain, cognition, or synaptic mechanisms). PMID 39300547
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Pharmacological inhibition of the CB1 cannabinoid receptor restores abnormal brain mitochondrial CB1 receptor expression and rescues bioenergetic and cognitive defects in a female mouse model of Rett syndrome.
Evidence row 861
Endocannabinoids modulates CB1; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain, cognition, or synaptic mechanisms). PMID 36613469
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Hippocampal Deletion of CB1 Receptor Impairs Social Memory and Leads to Age-Related Changes in the Hippocampus of Adult Mice.
Evidence row 862
Endocannabinoids modulates CB1; evidence class: insufficient (population or model: Animal model mentioned; study design: Narrative or expert review; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain, cognition, or synaptic mechanisms). PMID 16596773
Evidence class: insufficient; Study design: Narrative or expert review. Source: Analysis of the endocannabinoid system by using CB1 cannabinoid receptor knockout mice.
Evidence row 868
Endocannabinoids modulates CB2; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms). PMID 12505686
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinergic ligands.
Evidence row 872
Endocannabinoids modulates CB2; evidence class: insufficient (study design: Narrative or expert review; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms). PMID 28826535
Evidence class: insufficient; Study design: Narrative or expert review. Source: Functional Selectivity at Cannabinoid Receptors.
Evidence row 876
Endocannabinoids modulates CB2; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms). PMID 30639103
Evidence class: mechanistic or pharmacological. Source: Crystal Structure of the Human Cannabinoid Receptor CB2.
Evidence row 880
Endocannabinoids modulates CB2; evidence class: mechanistic or pharmacological (outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms). PMID 33749323
Evidence class: mechanistic or pharmacological. Source: CB2 cannabinoid receptor agonist selectively inhibits the mechanosensitivity of mucosal afferents in the guinea pig bladder.
Evidence row 888
Endocannabinoids modulates CB2; evidence class: mechanistic or pharmacological (outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms). PMID 36922494
Evidence class: mechanistic or pharmacological. Source: Structural basis of selective cannabinoid CB2 receptor activation.
Evidence row 889
Endocannabinoids modulates CB2; evidence class: insufficient (study design: Narrative or expert review; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms). PMID 38886185
Evidence class: insufficient; Study design: Narrative or expert review. Source: Patent review of cannabinoid receptor type 2 (CB2R) modulators (2016-present).
Evidence row 892
Endocannabinoids modulates CB2; evidence class: insufficient (study design: Narrative or expert review; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms). PMID 36028971
Evidence class: insufficient; Study design: Narrative or expert review. Source: Recent Advances on Type-2 Cannabinoid (CB2) Receptor Agonists and their Therapeutic Potential.
Evidence row 900
Endocannabinoids modulates CB2; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms). PMID 39264450
Evidence class: insufficient; Study design: Narrative or expert review. Source: Emerging roles of cannabinoid receptor CB2 receptor in the central nervous system: therapeutic target for CNS disorders.
Evidence row 902
Endocannabinoids modulates CB2; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms). PMID 37061199
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Cannabinoid CB2 receptors modulate alcohol induced behavior, and neuro-immune dysregulation in mice.
Evidence row 903
Endocannabinoids modulates CB2; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms). PMID 18615177
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: The cannabinoid CB2 receptor as a target for inflammation-dependent neurodegeneration.
Evidence row 908
Endocannabinoids modulates CB2; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms). PMID 23960212
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: CB1 and CB2 cannabinoid receptor antagonists prevent minocycline-induced neuroprotection following traumatic brain injury in mice.
Evidence row 917
Endocannabinoids modulates CB2; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms). PMID 24877594
Evidence class: insufficient; Study design: Narrative or expert review. Source: What we know and do not know about the cannabinoid receptor 2 (CB2).
Evidence row 929
Endocannabinoids modulates GPR55; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: GPR55 receptor activity, binding, signaling, or pharmacology). PMID 35862111
Evidence class: insufficient; Study design: Narrative or expert review. Source: Molecular networks underlying cannabinoid signaling in skeletal muscle plasticity.
Evidence row 930
Endocannabinoids modulates GPR55; evidence class: insufficient (study design: Narrative or expert review; outcome measure: GPR55 receptor activity, binding, signaling, or pharmacology). PMID 19647110
Evidence class: insufficient; Study design: Narrative or expert review. Source: Is GPR55 an anandamide receptor?
Evidence row 931
Endocannabinoids modulates GPR55; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: GPR55 receptor activity, binding, signaling, or pharmacology). PMID 18757503
Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: The GPR55 ligand L-alpha-lysophosphatidylinositol promotes RhoA-dependent Ca2+ signaling and NFAT activation.
Evidence row 937
Endocannabinoids modulates GPR55; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: GPR55 receptor activity, binding, signaling, or pharmacology). PMID 31527410
Evidence class: insufficient; Study design: Narrative or expert review. Source: The Endocannabinoid System of Animals.
Evidence row 941
Endocannabinoids modulates GPR55; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: GPR55 receptor activity, binding, signaling, or pharmacology). PMID 26408165
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabis and Endocannabinoid Signaling in Epilepsy.
Evidence row 947
Endocannabinoids modulates GPR18; evidence class: insufficient (study design: Narrative or expert review; outcome measure: GPR18 receptor activity, binding, signaling, or pharmacology). PMID 34676329
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoids in Gynecological Diseases.
Evidence row 948
Endocannabinoids modulates GPR18; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: GPR18 receptor activity, binding, signaling, or pharmacology). PMID 42114685
Evidence class: insufficient; Study design: Narrative or expert review. Source: Targeting GPR18: Structural modelling, ligand discovery, and therapeutic potential in neuroinflammatory disorders.
Evidence row 952
Endocannabinoids modulates GPR18; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: GPR18 receptor activity, binding, signaling, or pharmacology). PMID 29098189
Evidence class: insufficient; Study design: Narrative or expert review. Source: An Update on Non-CB1, Non-CB2 Cannabinoid Related G-Protein-Coupled Receptors.
Evidence row 953
Endocannabinoids modulates GPR18; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: GPR18 receptor activity, binding, signaling, or pharmacology). PMID 27018161
Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: GPR18 undergoes a high degree of constitutive trafficking but is unresponsive to N-Arachidonoyl Glycine.
Evidence row 954
Endocannabinoids modulates GPR18; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: GPR18 receptor activity, binding, signaling, or pharmacology). PMID 30871175
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Protective Effect of N-Arachidonoyl Glycine-GPR18 Signaling after Excitotoxical Lesion in Murine Organotypic Hippocampal Slice Cultures.
Evidence row 958
Endocannabinoids modulates GPR18; evidence class: insufficient (study design: Narrative or expert review; outcome measure: GPR18 receptor activity, binding, signaling, or pharmacology). PMID 29138268
Evidence class: insufficient; Study design: Narrative or expert review. Source: N-Acyl Amino Acids (Elmiric Acids): Endogenous Signaling Molecules with Therapeutic Potential.
Evidence row 961
Endocannabinoids modulates GPR18; evidence class: insufficient (population or model: Animal model mentioned; study design: Narrative or expert review; outcome measure: GPR18 receptor activity, binding, signaling, or pharmacology). PMID 18187165
Evidence class: insufficient; Study design: Narrative or expert review. Source: The elmiric acids: biologically active anandamide analogs.
Evidence row 963
Endocannabinoids modulates GPR119; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: GPR119 receptor activity, binding, signaling, metabolic physiology, or pharmacology). PMID 18426507
Evidence class: insufficient; Study design: Narrative or expert review. Source: Endocannabinoids and nutrition.
Evidence row 966
Endocannabinoids modulates GPR119; evidence class: insufficient (study design: Narrative or expert review; outcome measure: GPR119 receptor activity, binding, signaling, metabolic physiology, or pharmacology). PMID 19285259
Evidence class: insufficient; Study design: Narrative or expert review. Source: Role of acylethanolamides in the gastrointestinal tract with special reference to food intake and energy balance.
Evidence row 967
Endocannabinoids modulates GPR119; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: GPR119 receptor activity, binding, signaling, metabolic physiology, or pharmacology). PMID 23074242
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Regulation of GPR119 receptor activity with endocannabinoid-like lipids.
Evidence row 968
Endocannabinoids modulates GPR119; evidence class: preliminary human (population or model: Human participants or patients mentioned; outcome measure: GPR119 receptor activity, binding, signaling, metabolic physiology, or pharmacology). PMID 30787385
Evidence class: preliminary human. Source: Members of the endocannabinoid system are distinctly regulated in inflammatory bowel disease and colorectal cancer.
Evidence row 969
Endocannabinoids modulates GPR119; evidence class: insufficient (study design: Narrative or expert review; outcome measure: GPR119 receptor activity, binding, signaling, metabolic physiology, or pharmacology). PMID 42144898
Evidence class: insufficient; Study design: Narrative or expert review. Source: Fatty acid amide hydrolase (FAAH) and the endocannabinoid system in obesity: Mechanistic insights and pharmacological opportunities beyond incretin-based therapies.
Evidence row 970
Endocannabinoids modulates GPR119; evidence class: insufficient (study design: Narrative or expert review; outcome measure: GPR119 receptor activity, binding, signaling, metabolic physiology, or pharmacology). PMID 30537148
Evidence class: insufficient; Study design: Narrative or expert review. Source: Oleoylethanolamide: A novel pharmaceutical agent in the management of obesity-an updated review.
Evidence row 980
Endocannabinoids modulates TRPV1; evidence class: insufficient (population or model: Animal model mentioned; study design: Narrative or expert review; outcome measure: TRPV1 channel activity, desensitization, binding, signaling, or pharmacology). PMID 36222019
Evidence class: insufficient; Study design: Narrative or expert review. Source: Endocannabinoid signaling in microglia.
Evidence row 982
Endocannabinoids modulates TRPV1; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: TRPV1 channel activity, desensitization, binding, signaling, or pharmacology). PMID 31408376
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: The TRPV1 channel regulates glucose metabolism.
Evidence row 987
Endocannabinoids modulates TRPV1; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: TRPV1 channel activity, desensitization, binding, signaling, or pharmacology). PMID 27179600
Evidence class: insufficient; Study design: Narrative or expert review. Source: Beyond Cannabis: Plants and the Endocannabinoid System.
Evidence row 1023
Endocannabinoids modulates TRPV4; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Human clinical study; outcome measure: TRPV4 channel activity, binding, signaling, or pharmacology). PMID 38750093
Evidence class: mechanistic or pharmacological; Study design: Human clinical study. Source: Transcriptomic signature, bioactivity and safety of a non-hepatotoxic analgesic generating AM404 in the midbrain PAG region.
Evidence row 1025
Endocannabinoids modulates TRPV4; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: TRPV4 channel activity, binding, signaling, or pharmacology). PMID 26990140
Evidence class: insufficient; Study design: Narrative or expert review. Source: Potential Future Pharmacological Treatment of Bladder Dysfunction.
Evidence row 1027
Endocannabinoids modulates TRPV4; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: TRPV4 channel activity, binding, signaling, or pharmacology). PMID 26294342
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Role of endothelial TRPV4 channels in vascular actions of the endocannabinoid, 2-arachidonoylglycerol.
Evidence row 1041
Endocannabinoids modulates TRPA1; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: TRPA1 channel activity, desensitization, binding, signaling, or pharmacology). PMID 25065940
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Structure-affinity relationships and pharmacological characterization of new alkyl-resorcinol cannabinoid receptor ligands: Identification of a dual cannabinoid receptor/TRPA1 channel agonist.
Evidence row 1059
Endocannabinoids modulates TRPM8; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: TRPM8 channel activity, binding, signaling, or pharmacology). PMID 39684707
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: TRPM8's Role in the Shift Between Opioid and Cannabinoid Pathways in Electroacupuncture for Inflammatory Pain in Mice.
Evidence row 1061
Endocannabinoids modulates TRPM8; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: TRPM8 channel activity, binding, signaling, or pharmacology). PMID 17428469
Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Regulation of transient receptor potential channels of melastatin type 8 (TRPM8): effect of cAMP, cannabinoid CB(1) receptors and endovanilloids.

Source Trail

Source-backed evidence table and references

95 research sources

This section is the technical source layer under the overview. It keeps grouped evidence buckets, evidence rows, PubMed or DOI links, related pages, and references visible for audit and revision.

Plain-Language Summary

This page has 96 source-backed evidence row(s) from 95 source(s).

Identity

Canonical name: endocannabinoids
Type: other
Subtype: lipid_class
Description: Not recorded

Evidence Snapshot

Evidence rows: 96
Sources: 95
Evidence classes: insufficient (59), mechanistic or pharmacological (31), preclinical (2), preliminary human (4)
Draft sections: human evidence (3), mechanistic evidence (30), preclinical evidence (2), safety (12), uncertainty (49)

Key Draft Sections

Human evidence: 3 evidence row(s).
Safety and tolerability: 12 evidence row(s).
Uncertainty and gaps: 49 evidence row(s).
Preclinical evidence: 2 evidence row(s).
Mechanistic evidence: 30 evidence row(s).

Evidence Relationships

Subject	Relationship	Object Or Focus	Evidence Summary	Sources	Evidence Rows
Endocannabinoids	studied for	Cannabinoids and immune modulation research outcomes	Mechanistic research summary: mechanistic or pharmacological (3)	3	3 rows (268-272)
Endocannabinoids	modulates	CB1	Mechanistic research summary: insufficient (11), mechanistic or pharmacological (5)	16	16 rows (814-862)
Endocannabinoids	modulates	CB2	Mechanistic research summary: insufficient (6), mechanistic or pharmacological (6)	12	12 rows (868-917)
Endocannabinoids	modulates	endocannabinoid enzyme activity or metabolic mechanisms	Developed but mixed human research summary: insufficient (6), mechanistic or pharmacological (3), preclinical (2), preliminary human (1)	12	12 rows (300-314)
Endocannabinoids	studied for	Endocannabinoids and endocannabinoid-like lipids research topics	Developed but mixed human research summary: insufficient (6), mechanistic or pharmacological (1), preliminary human (1)	8	8 rows (202-299)
Endocannabinoids	modulates	GPR119	Developed but mixed human research summary: insufficient (4), mechanistic or pharmacological (1), preliminary human (1)	6	6 rows (963-970)
Endocannabinoids	modulates	GPR18	Mechanistic research summary: insufficient (5), mechanistic or pharmacological (2)	7	7 rows (947-961)
Endocannabinoids	modulates	GPR55	Mechanistic research summary: insufficient (4), mechanistic or pharmacological (1)	5	5 rows (929-941)
Endocannabinoids	modulates	receptor, target, or pharmacology mechanisms	Mechanistic research summary: insufficient (4), mechanistic or pharmacological (2)	6	6 rows (209-265)
Endocannabinoids	studied for	safety, risk, adverse-event, or formulation-specific concerns	Developed but mixed human research summary: insufficient (10), mechanistic or pharmacological (1), preliminary human (1)	12	12 rows (222-347)
Endocannabinoids	modulates	TRPA1	Mechanistic research summary: mechanistic or pharmacological (1)	1	1041
Endocannabinoids	modulates	TRPM8	Mechanistic research summary: mechanistic or pharmacological (2)	2	2 rows (1059-1061)
Endocannabinoids	modulates	TRPV1	Mechanistic research summary: insufficient (2), mechanistic or pharmacological (1)	3	3 rows (980-987)
Endocannabinoids	modulates	TRPV4	Mechanistic research summary: insufficient (1), mechanistic or pharmacological (2)	3	3 rows (1023-1027)

Source-Backed Evidence Table

Evidence Row	Statement	Source
202	Endocannabinoids studied for Endocannabinoids and endocannabinoid-like lipids research topics; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: Endocannabinoids and endocannabinoid-like lipids research topics).	Endocannabinoids and endocannabinoid-like compounds modulate hypoxia-induced permeability in CaCo-2 cells via CB1, TRPV1, and PPARα.PubMed 31325449 DOI 10.1016/j.bcp.2019.07.017
209	Endocannabinoids modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: receptor, target, or pharmacology mechanisms).	Potential metabolic and behavioural roles of the putative endocannabinoid receptors GPR18, GPR55 and GPR119 in feeding.PubMed 31146657 DOI 10.2174/1570159x17666190118143014
210	Endocannabinoids modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: receptor, target, or pharmacology mechanisms).	Some Prospective Alternatives for Treating Pain: The Endocannabinoid System and Its Putative Receptors GPR18 and GPR55.PubMed 30670965 DOI 10.3389/fphar.2018.01496
222	Endocannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: safety, risk, adverse-event, or formulation-specific concerns).	Role of cannabis in cardiovascular disorders.PubMed 28840009 DOI 10.21037/jtd.2017.06.104
237	Endocannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient (study design: Narrative or expert review; outcome measure: safety, risk, adverse-event, or formulation-specific concerns).	Cannabinoids and monoaminergic system: implications for learning and memory.PubMed 39206116 DOI 10.3389/fnins.2024.1425532
238	Endocannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: preliminary human (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Human clinical study; outcome measure: safety, risk, adverse-event, or formulation-specific concerns).	Adverse Effects of Recreational and Medical Cannabis.PubMed 33897066 DOI 10.64719/pb.4395
241	Endocannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient (study design: Narrative or expert review; outcome measure: safety, risk, adverse-event, or formulation-specific concerns).	Endocannabinoid signaling and long-term synaptic plasticity.PubMed 19575681 DOI 10.1146/annurev.physiol.010908.163149
258	Endocannabinoids modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient (study design: Systematic review; outcome measure: receptor, target, or pharmacology mechanisms).	Cys-loop receptors on cannabinoids: All high?PubMed 36439263 DOI 10.3389/fphys.2022.1044575
260	Endocannabinoids modulates receptor, target, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: receptor, target, or pharmacology mechanisms).	Subunit-specific modulation of glycine receptors by cannabinoids and N-arachidonyl-glycine.PubMed 18755158 DOI 10.1016/j.bcp.2008.07.037
262	Endocannabinoids modulates receptor, target, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: receptor, target, or pharmacology mechanisms).	Glycine receptors in CNS neurons as a target for nonretrograde action of cannabinoids.PubMed 16107637 DOI 10.1523/jneurosci.0977-05.2005
265	Endocannabinoids modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: receptor, target, or pharmacology mechanisms).	Cannabinoids in Parkinson's Disease.PubMed 28861502 DOI 10.1089/can.2017.0002
268	Endocannabinoids studied for Cannabinoids and immune modulation research outcomes; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: Cannabinoids and immune modulation research outcomes).	Astrocytic cannabinoid receptor 1 promotes resilience by dampening stress-induced blood-brain barrier alterations.PubMed 40016352 DOI 10.1038/s41593-025-01891-9
271	Endocannabinoids studied for Cannabinoids and immune modulation research outcomes; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: Cannabinoids and immune modulation research outcomes).	Phospholipase Cγ2 regulates endocannabinoid and eicosanoid networks in innate immune cells.PubMed 34607960 DOI 10.1073/pnas.2112971118
272	Endocannabinoids studied for Cannabinoids and immune modulation research outcomes; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: Cannabinoids and immune modulation research outcomes).	Impact of Chronic Moderate Exercise on Immune Cells and Cytokine Levels in Rats: Focus on the Endocannabinergic Pathway.PubMed 37962860 DOI 10.1089/jir.2023.0120
290	Endocannabinoids studied for Endocannabinoids and endocannabinoid-like lipids research topics; evidence class: insufficient (study design: Narrative or expert review; outcome measure: Endocannabinoids and endocannabinoid-like lipids research topics).	Endocannabinoid Turnover.PubMed 28826539 DOI 10.1016/bs.apha.2017.03.006
291	Endocannabinoids studied for Endocannabinoids and endocannabinoid-like lipids research topics; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: Endocannabinoids and endocannabinoid-like lipids research topics).	Endocannabinoids.PubMed 9831287 DOI 10.1016/s0014-2999(98
295	Endocannabinoids studied for Endocannabinoids and endocannabinoid-like lipids research topics; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: Endocannabinoids and endocannabinoid-like lipids research topics).	Classical endocannabinoid-like compounds and their regulation by nutrients.PubMed 24677570 DOI 10.1002/biof.1158
296	Endocannabinoids studied for Endocannabinoids and endocannabinoid-like lipids research topics; evidence class: insufficient (outcome measure: Endocannabinoids and endocannabinoid-like lipids research topics).	Effects of fermentation and alkalisation on the formation of endocannabinoid-like compounds in olives.PubMed 38909454 DOI 10.1016/j.foodchem.2024.140164
297	Endocannabinoids studied for Endocannabinoids and endocannabinoid-like lipids research topics; evidence class: insufficient (outcome measure: Endocannabinoids and endocannabinoid-like lipids research topics).	Endocannabinoids, endocannabinoid-like compounds and cortisone in head hair of health care workers as markers of stress and resilience during the early COVID-19 pandemic.PubMed 38296973 DOI 10.1038/s41398-024-02771-9
298	Endocannabinoids studied for Endocannabinoids and endocannabinoid-like lipids research topics; evidence class: insufficient (outcome measure: Endocannabinoids and endocannabinoid-like lipids research topics).	Roles of Endocannabinoids and Endocannabinoid-Like Molecules in Energy Homeostasis and Metabolic Regulation: A Nutritional Perspective.PubMed 34115519 DOI 10.1146/annurev-nutr-043020-090216
299	Endocannabinoids studied for Endocannabinoids and endocannabinoid-like lipids research topics; evidence class: preliminary human (population or model: Human participants or patients mentioned; outcome measure: Endocannabinoids and endocannabinoid-like lipids research topics).	Liquid Chromatography-Tandem Mass Spectrometry Method for Simultaneous Quantification of Four Endocannabinoids and Endocannabinoid-Like Substances in Plasma: Application in an HIV-Hepatitis C Virus Coinfected Population.PubMed 41035123 DOI 10.1097/ftd.0000000000001397
300	Endocannabinoids modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms).	Potential application of endocannabinoid system agents in neuropsychiatric and neurodegenerative diseases-focusing on FAAH/MAGL inhibitors.PubMed 32203086 DOI 10.1038/s41401-020-0385-7
301	Endocannabinoids modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms).	Inhibition of endocannabinoid hydrolases MAGL, FAAH and ABHD6 by AKU-005 reduces ex vivo cortical spreading depression.PubMed 40269679 DOI 10.1186/s10194-025-02030-2
302	Endocannabinoids modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms).	The role of endocannabinoid pathway in the neuropathology of Alzheimer's disease: Can the inhibitors of MAGL and FAAH prove to be potential therapeutic targets against the cognitive impairment associated with Alzheimer's disease?PubMed 34217798 DOI 10.1016/j.brainresbull.2021.06.022
304	Endocannabinoids modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms).	Potential of Fatty Acid Amide Hydrolase (FAAH), Monoacylglycerol Lipase (MAGL), and Diacylglycerol Lipase (DAGL) Enzymes as Targets for Obesity Treatment: A Narrative Review.PubMed 34959715 DOI 10.3390/ph14121316
305	Endocannabinoids modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms).	Inhibition of endocannabinoid synthesis enzymes DAGL and NAPE-PLD transiently lowers body weight and alters glucose homeostasis during a high-fat diet challenge in mice.PubMed 41092478 DOI 10.1093/ejendo/lvaf212
306	Endocannabinoids modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: preclinical (population or model: Animal model mentioned; study design: Animal study; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms).	Subcellular localization of NAPE-PLD and DAGL-α in the ventromedial nucleus of the hypothalamus by a preembedding immunogold method.PubMed 24346263 DOI 10.1007/s00418-013-1174-x
307	Endocannabinoids modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms).	Microglial morphological/inflammatory phenotypes and endocannabinoid signaling in a preclinical model of periodontitis and depression.PubMed 39245706 DOI 10.1186/s12974-024-03213-5
308	Endocannabinoids modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms).	Critical enzymes involved in endocannabinoid metabolism.PubMed 17346227 DOI 10.2174/092986607780090829
310	Endocannabinoids modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms).	Structural properties and role of the endocannabinoid lipases ABHD6 and ABHD12 in lipid signalling and disease.PubMed 30564946 DOI 10.1007/s00726-018-2682-8
312	Endocannabinoids modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms).	The serine hydrolases MAGL, ABHD6 and ABHD12 as guardians of 2-arachidonoylglycerol signalling through cannabinoid receptors.PubMed 21418147 DOI 10.1111/j.1748-1716.2011.02280.x
313	Endocannabinoids modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: preclinical (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms).	Deregulation of the endocannabinoid system and therapeutic potential of ABHD6 blockade in the cuprizone model of demyelination.PubMed 30075103 DOI 10.1016/j.bcp.2018.07.042
314	Endocannabinoids modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: preliminary human (population or model: Human participants or patients mentioned; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms).	Biochemical and pharmacological characterization of human α/β-hydrolase domain containing 6 (ABHD6) and 12 (ABHD12).PubMed 22969151 DOI 10.1194/jlr.m030411
319	Endocannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: safety, risk, adverse-event, or formulation-specific concerns).	Endocannabinoids, blood pressure and the human heart.PubMed 18426501 DOI 10.1111/j.1365-2826.2008.01677.x
336	Endocannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient (study design: Narrative or expert review; outcome measure: safety, risk, adverse-event, or formulation-specific concerns).	The potential role of cannabinoids in dermatology.PubMed 31599175 DOI 10.1080/09546634.2019.1675854
339	Endocannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: safety, risk, adverse-event, or formulation-specific concerns).	Cannabinoids and Their Receptors in Skin Diseases.PubMed 38003712 DOI 10.3390/ijms242216523
343	Endocannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient (study design: Narrative or expert review; outcome measure: safety, risk, adverse-event, or formulation-specific concerns).	Endocannabinoid system and its modulation of brain, gut, joint and skin inflammation.PubMed 33909195 DOI 10.1007/s11033-021-06366-1
344	Endocannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient (study design: Narrative or expert review; outcome measure: safety, risk, adverse-event, or formulation-specific concerns).	The endocannabinoid system of the skin. A potential approach for the treatment of skin disorders.PubMed 30138623 DOI 10.1016/j.bcp.2018.08.022
345	Endocannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: safety, risk, adverse-event, or formulation-specific concerns).	Sebaceous immunobiology - skin homeostasis, pathophysiology, coordination of innate immunity and inflammatory response and disease associations.PubMed 36439142 DOI 10.3389/fimmu.2022.1029818
346	Endocannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: safety, risk, adverse-event, or formulation-specific concerns).	The endocannabinoid system of the skin in health and disease: novel perspectives and therapeutic opportunities.PubMed 19608284 DOI 10.1016/j.tips.2009.05.004
347	Endocannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: safety, risk, adverse-event, or formulation-specific concerns).	Modulators of the endocannabinoid system influence skin barrier repair, epidermal proliferation, differentiation and inflammation in a mouse model.PubMed 31350927 DOI 10.1111/exd.14012
814	Endocannabinoids modulates CB1; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms).	Cannabinergic ligands.PubMed 12505686 DOI 10.1016/s0009-3084(02
815	Endocannabinoids modulates CB1; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms).	Assay of CB1 Receptor Binding.PubMed 27245890 DOI 10.1007/978-1-4939-3539-0_5
818	Endocannabinoids modulates CB1; evidence class: insufficient (study design: Narrative or expert review; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms).	Allosteric Modulation: An Alternate Approach Targeting the Cannabinoid CB1 Receptor.PubMed 27879006 DOI 10.1002/med.21418
827	Endocannabinoids modulates CB1; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms).	Endocannabinoids and Their Pharmacological Actions.PubMed 26408156 DOI 10.1007/978-3-319-20825-1_1
833	Endocannabinoids modulates CB1; evidence class: insufficient (study design: Narrative or expert review; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms).	Cannabinoid receptor 1 ligands: Biased signaling mechanisms driving functionally selective drug discovery.PubMed 39828030 DOI 10.1016/j.pharmthera.2025.108795
836	Endocannabinoids modulates CB1; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms).	Synthesis and Pharmacological Characterization of a Novel Cannabinoid Receptor 1 Antagonist.PubMed 40521518 DOI 10.1021/acsomega.4c11355
842	Endocannabinoids modulates CB1; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain, cognition, or synaptic mechanisms).	Cannabinoid-based therapy as a future for joint degeneration. Focus on the role of CB2 receptor in the arthritis progression and pain: an updated review.PubMed 34050525 DOI 10.1007/s43440-021-00270-y
846	Endocannabinoids modulates CB1; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain, cognition, or synaptic mechanisms).	The pharmacology of cannabinoid receptors and their ligands: an overview.PubMed 16570099 DOI 10.1038/sj.ijo.0803272
847	Endocannabinoids modulates CB1; evidence class: insufficient (study design: Narrative or expert review; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain, cognition, or synaptic mechanisms).	Latest advances in cannabinoid receptor agonists.PubMed 19939187 DOI 10.1517/13543770903436505
849	Endocannabinoids modulates CB1; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain, cognition, or synaptic mechanisms).	Therapeutic potential of cannabinoid receptor 2 in the treatment of diabetes mellitus and its complications.PubMed 31461639 DOI 10.1016/j.ejphar.2019.172628
850	Endocannabinoids modulates CB1; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain, cognition, or synaptic mechanisms).	The endocannabinoid system: physiology and pharmacology.PubMed 15550444 DOI 10.1093/alcalc/agh110
853	Endocannabinoids modulates CB1; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain, cognition, or synaptic mechanisms).	Restoration of CB1 receptor function in hippocampal GABAergic neurons rescues memory deficits in Huntington's disease models.PubMed 40855505 DOI 10.1186/s40035-025-00500-w
855	Endocannabinoids modulates CB1; evidence class: insufficient (study design: Narrative or expert review; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain, cognition, or synaptic mechanisms).	Astroglial type-1 cannabinoid receptor (CB1): A new player in the tripartite synapse.PubMed 25967266 DOI 10.1016/j.neuroscience.2015.05.002
857	Endocannabinoids modulates CB1; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain, cognition, or synaptic mechanisms).	Pharmacological inhibition of the CB1 cannabinoid receptor restores abnormal brain mitochondrial CB1 receptor expression and rescues bioenergetic and cognitive defects in a female mouse model of Rett syndrome.PubMed 39300547 DOI 10.1186/s13229-024-00617-1
861	Endocannabinoids modulates CB1; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain, cognition, or synaptic mechanisms).	Hippocampal Deletion of CB1 Receptor Impairs Social Memory and Leads to Age-Related Changes in the Hippocampus of Adult Mice.PubMed 36613469 DOI 10.3390/ijms24010026
862	Endocannabinoids modulates CB1; evidence class: insufficient (population or model: Animal model mentioned; study design: Narrative or expert review; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain, cognition, or synaptic mechanisms).	Analysis of the endocannabinoid system by using CB1 cannabinoid receptor knockout mice.PubMed 16596773 DOI 10.1007/3-540-26573-2_4
868	Endocannabinoids modulates CB2; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms).	Cannabinergic ligands.PubMed 12505686 DOI 10.1016/s0009-3084(02
872	Endocannabinoids modulates CB2; evidence class: insufficient (study design: Narrative or expert review; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms).	Functional Selectivity at Cannabinoid Receptors.PubMed 28826535 DOI 10.1016/bs.apha.2017.03.005
876	Endocannabinoids modulates CB2; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms).	Crystal Structure of the Human Cannabinoid Receptor CB2.PubMed 30639103 DOI 10.1016/j.cell.2018.12.011
880	Endocannabinoids modulates CB2; evidence class: mechanistic or pharmacological (outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms).	CB2 cannabinoid receptor agonist selectively inhibits the mechanosensitivity of mucosal afferents in the guinea pig bladder.PubMed 33749323 DOI 10.1152/ajprenal.00065.2021
888	Endocannabinoids modulates CB2; evidence class: mechanistic or pharmacological (outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms).	Structural basis of selective cannabinoid CB2 receptor activation.PubMed 36922494 DOI 10.1038/s41467-023-37112-9
889	Endocannabinoids modulates CB2; evidence class: insufficient (study design: Narrative or expert review; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms).	Patent review of cannabinoid receptor type 2 (CB2R) modulators (2016-present).PubMed 38886185 DOI 10.1080/13543776.2024.2368745
892	Endocannabinoids modulates CB2; evidence class: insufficient (study design: Narrative or expert review; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms).	Recent Advances on Type-2 Cannabinoid (CB2) Receptor Agonists and their Therapeutic Potential.PubMed 36028971 DOI 10.2174/0929867329666220825161603
900	Endocannabinoids modulates CB2; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms).	Emerging roles of cannabinoid receptor CB2 receptor in the central nervous system: therapeutic target for CNS disorders.PubMed 39264450 DOI 10.1007/s00213-024-06683-w
902	Endocannabinoids modulates CB2; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms).	Cannabinoid CB2 receptors modulate alcohol induced behavior, and neuro-immune dysregulation in mice.PubMed 37061199 DOI 10.1016/j.bbr.2023.114439
903	Endocannabinoids modulates CB2; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms).	The cannabinoid CB2 receptor as a target for inflammation-dependent neurodegeneration.PubMed 18615177 DOI 10.2174/157015907780866884
908	Endocannabinoids modulates CB2; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms).	CB1 and CB2 cannabinoid receptor antagonists prevent minocycline-induced neuroprotection following traumatic brain injury in mice.PubMed 23960212 DOI 10.1093/cercor/bht202
917	Endocannabinoids modulates CB2; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms).	What we know and do not know about the cannabinoid receptor 2 (CB2).PubMed 24877594 DOI 10.1016/j.smim.2014.04.002
929	Endocannabinoids modulates GPR55; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: GPR55 receptor activity, binding, signaling, or pharmacology).	Molecular networks underlying cannabinoid signaling in skeletal muscle plasticity.PubMed 35862111 DOI 10.1002/jcp.30837
930	Endocannabinoids modulates GPR55; evidence class: insufficient (study design: Narrative or expert review; outcome measure: GPR55 receptor activity, binding, signaling, or pharmacology).	Is GPR55 an anandamide receptor?PubMed 19647110 DOI 10.1016/s0083-6729(09
931	Endocannabinoids modulates GPR55; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: GPR55 receptor activity, binding, signaling, or pharmacology).	The GPR55 ligand L-alpha-lysophosphatidylinositol promotes RhoA-dependent Ca2+ signaling and NFAT activation.PubMed 18757503 DOI 10.1096/fj.08-108670
937	Endocannabinoids modulates GPR55; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: GPR55 receptor activity, binding, signaling, or pharmacology).	The Endocannabinoid System of Animals.PubMed 31527410 DOI 10.3390/ani9090686
941	Endocannabinoids modulates GPR55; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: GPR55 receptor activity, binding, signaling, or pharmacology).	Cannabis and Endocannabinoid Signaling in Epilepsy.PubMed 26408165 DOI 10.1007/978-3-319-20825-1_10
947	Endocannabinoids modulates GPR18; evidence class: insufficient (study design: Narrative or expert review; outcome measure: GPR18 receptor activity, binding, signaling, or pharmacology).	Cannabinoids in Gynecological Diseases.PubMed 34676329 DOI 10.1159/000499164
948	Endocannabinoids modulates GPR18; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: GPR18 receptor activity, binding, signaling, or pharmacology).	Targeting GPR18: Structural modelling, ligand discovery, and therapeutic potential in neuroinflammatory disorders.PubMed 42114685 DOI 10.1016/j.bcp.2026.118038
952	Endocannabinoids modulates GPR18; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: GPR18 receptor activity, binding, signaling, or pharmacology).	An Update on Non-CB1, Non-CB2 Cannabinoid Related G-Protein-Coupled Receptors.PubMed 29098189 DOI 10.1089/can.2017.0036
953	Endocannabinoids modulates GPR18; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: GPR18 receptor activity, binding, signaling, or pharmacology).	GPR18 undergoes a high degree of constitutive trafficking but is unresponsive to N-Arachidonoyl Glycine.PubMed 27018161 DOI 10.7717/peerj.1835
954	Endocannabinoids modulates GPR18; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: GPR18 receptor activity, binding, signaling, or pharmacology).	Protective Effect of N-Arachidonoyl Glycine-GPR18 Signaling after Excitotoxical Lesion in Murine Organotypic Hippocampal Slice Cultures.PubMed 30871175 DOI 10.3390/ijms20061266
958	Endocannabinoids modulates GPR18; evidence class: insufficient (study design: Narrative or expert review; outcome measure: GPR18 receptor activity, binding, signaling, or pharmacology).	N-Acyl Amino Acids (Elmiric Acids): Endogenous Signaling Molecules with Therapeutic Potential.PubMed 29138268 DOI 10.1124/mol.117.110841
961	Endocannabinoids modulates GPR18; evidence class: insufficient (population or model: Animal model mentioned; study design: Narrative or expert review; outcome measure: GPR18 receptor activity, binding, signaling, or pharmacology).	The elmiric acids: biologically active anandamide analogs.PubMed 18187165 DOI 10.1016/j.neuropharm.2007.11.011
963	Endocannabinoids modulates GPR119; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: GPR119 receptor activity, binding, signaling, metabolic physiology, or pharmacology).	Endocannabinoids and nutrition.PubMed 18426507 DOI 10.1111/j.1365-2826.2008.01687.x
966	Endocannabinoids modulates GPR119; evidence class: insufficient (study design: Narrative or expert review; outcome measure: GPR119 receptor activity, binding, signaling, metabolic physiology, or pharmacology).	Role of acylethanolamides in the gastrointestinal tract with special reference to food intake and energy balance.PubMed 19285259 DOI 10.1016/j.beem.2008.10.003
967	Endocannabinoids modulates GPR119; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: GPR119 receptor activity, binding, signaling, metabolic physiology, or pharmacology).	Regulation of GPR119 receptor activity with endocannabinoid-like lipids.PubMed 23074242 DOI 10.1152/ajpendo.00269.2012
968	Endocannabinoids modulates GPR119; evidence class: preliminary human (population or model: Human participants or patients mentioned; outcome measure: GPR119 receptor activity, binding, signaling, metabolic physiology, or pharmacology).	Members of the endocannabinoid system are distinctly regulated in inflammatory bowel disease and colorectal cancer.PubMed 30787385 DOI 10.1038/s41598-019-38865-4
969	Endocannabinoids modulates GPR119; evidence class: insufficient (study design: Narrative or expert review; outcome measure: GPR119 receptor activity, binding, signaling, metabolic physiology, or pharmacology).	Fatty acid amide hydrolase (FAAH) and the endocannabinoid system in obesity: Mechanistic insights and pharmacological opportunities beyond incretin-based therapies.PubMed 42144898 DOI 10.1111/bph.70511
970	Endocannabinoids modulates GPR119; evidence class: insufficient (study design: Narrative or expert review; outcome measure: GPR119 receptor activity, binding, signaling, metabolic physiology, or pharmacology).	Oleoylethanolamide: A novel pharmaceutical agent in the management of obesity-an updated review.PubMed 30537148 DOI 10.1002/jcp.27913
980	Endocannabinoids modulates TRPV1; evidence class: insufficient (population or model: Animal model mentioned; study design: Narrative or expert review; outcome measure: TRPV1 channel activity, desensitization, binding, signaling, or pharmacology).	Endocannabinoid signaling in microglia.PubMed 36222019 DOI 10.1002/glia.24281
982	Endocannabinoids modulates TRPV1; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: TRPV1 channel activity, desensitization, binding, signaling, or pharmacology).	The TRPV1 channel regulates glucose metabolism.PubMed 31408376 DOI 10.1152/ajpendo.00102.2019
987	Endocannabinoids modulates TRPV1; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: TRPV1 channel activity, desensitization, binding, signaling, or pharmacology).	Beyond Cannabis: Plants and the Endocannabinoid System.PubMed 27179600 DOI 10.1016/j.tips.2016.04.005
1023	Endocannabinoids modulates TRPV4; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Human clinical study; outcome measure: TRPV4 channel activity, binding, signaling, or pharmacology).	Transcriptomic signature, bioactivity and safety of a non-hepatotoxic analgesic generating AM404 in the midbrain PAG region.PubMed 38750093 DOI 10.1038/s41598-024-61791-z
1025	Endocannabinoids modulates TRPV4; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: TRPV4 channel activity, binding, signaling, or pharmacology).	Potential Future Pharmacological Treatment of Bladder Dysfunction.PubMed 26990140 DOI 10.1111/bcpt.12577
1027	Endocannabinoids modulates TRPV4; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: TRPV4 channel activity, binding, signaling, or pharmacology).	Role of endothelial TRPV4 channels in vascular actions of the endocannabinoid, 2-arachidonoylglycerol.PubMed 26294342 DOI 10.1111/bph.13312
1041	Endocannabinoids modulates TRPA1; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: TRPA1 channel activity, desensitization, binding, signaling, or pharmacology).	Structure-affinity relationships and pharmacological characterization of new alkyl-resorcinol cannabinoid receptor ligands: Identification of a dual cannabinoid receptor/TRPA1 channel agonist.PubMed 25065940 DOI 10.1016/j.bmc.2014.07.006
1059	Endocannabinoids modulates TRPM8; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: TRPM8 channel activity, binding, signaling, or pharmacology).	TRPM8's Role in the Shift Between Opioid and Cannabinoid Pathways in Electroacupuncture for Inflammatory Pain in Mice.PubMed 39684707 DOI 10.3390/ijms252313000
1061	Endocannabinoids modulates TRPM8; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: TRPM8 channel activity, binding, signaling, or pharmacology).	Regulation of transient receptor potential channels of melastatin type 8 (TRPM8): effect of cAMP, cannabinoid CB(1) receptors and endovanilloids.PubMed 17428469 DOI 10.1016/j.yexcr.2007.01.008

CB1
CB2
GPR119
GPR18
GPR55
TRPA1
TRPM8
TRPV1
TRPV4

References

Endocannabinoids and endocannabinoid-like compounds modulate hypoxia-induced permeability in CaCo-2 cells via CB1, TRPV1, and PPARα.PubMed 31325449 DOI 10.1016/j.bcp.2019.07.017
Potential metabolic and behavioural roles of the putative endocannabinoid receptors GPR18, GPR55 and GPR119 in feeding.PubMed 31146657 DOI 10.2174/1570159x17666190118143014
Some Prospective Alternatives for Treating Pain: The Endocannabinoid System and Its Putative Receptors GPR18 and GPR55.PubMed 30670965 DOI 10.3389/fphar.2018.01496
Role of cannabis in cardiovascular disorders.PubMed 28840009 DOI 10.21037/jtd.2017.06.104
Cannabinoids and monoaminergic system: implications for learning and memory.PubMed 39206116 DOI 10.3389/fnins.2024.1425532
Adverse Effects of Recreational and Medical Cannabis.PubMed 33897066 DOI 10.64719/pb.4395
Endocannabinoid signaling and long-term synaptic plasticity.PubMed 19575681 DOI 10.1146/annurev.physiol.010908.163149
Cys-loop receptors on cannabinoids: All high?PubMed 36439263 DOI 10.3389/fphys.2022.1044575
Subunit-specific modulation of glycine receptors by cannabinoids and N-arachidonyl-glycine.PubMed 18755158 DOI 10.1016/j.bcp.2008.07.037
Glycine receptors in CNS neurons as a target for nonretrograde action of cannabinoids.PubMed 16107637 DOI 10.1523/jneurosci.0977-05.2005
Cannabinoids in Parkinson's Disease.PubMed 28861502 DOI 10.1089/can.2017.0002
Astrocytic cannabinoid receptor 1 promotes resilience by dampening stress-induced blood-brain barrier alterations.PubMed 40016352 DOI 10.1038/s41593-025-01891-9
Phospholipase Cγ2 regulates endocannabinoid and eicosanoid networks in innate immune cells.PubMed 34607960 DOI 10.1073/pnas.2112971118
Impact of Chronic Moderate Exercise on Immune Cells and Cytokine Levels in Rats: Focus on the Endocannabinergic Pathway.PubMed 37962860 DOI 10.1089/jir.2023.0120
Endocannabinoid Turnover.PubMed 28826539 DOI 10.1016/bs.apha.2017.03.006
Endocannabinoids.PubMed 9831287 DOI 10.1016/s0014-2999(98
Classical endocannabinoid-like compounds and their regulation by nutrients.PubMed 24677570 DOI 10.1002/biof.1158
Effects of fermentation and alkalisation on the formation of endocannabinoid-like compounds in olives.PubMed 38909454 DOI 10.1016/j.foodchem.2024.140164
Endocannabinoids, endocannabinoid-like compounds and cortisone in head hair of health care workers as markers of stress and resilience during the early COVID-19 pandemic.PubMed 38296973 DOI 10.1038/s41398-024-02771-9
Roles of Endocannabinoids and Endocannabinoid-Like Molecules in Energy Homeostasis and Metabolic Regulation: A Nutritional Perspective.PubMed 34115519 DOI 10.1146/annurev-nutr-043020-090216
Liquid Chromatography-Tandem Mass Spectrometry Method for Simultaneous Quantification of Four Endocannabinoids and Endocannabinoid-Like Substances in Plasma: Application in an HIV-Hepatitis C Virus Coinfected Population.PubMed 41035123 DOI 10.1097/ftd.0000000000001397
Potential application of endocannabinoid system agents in neuropsychiatric and neurodegenerative diseases-focusing on FAAH/MAGL inhibitors.PubMed 32203086 DOI 10.1038/s41401-020-0385-7
Inhibition of endocannabinoid hydrolases MAGL, FAAH and ABHD6 by AKU-005 reduces ex vivo cortical spreading depression.PubMed 40269679 DOI 10.1186/s10194-025-02030-2
The role of endocannabinoid pathway in the neuropathology of Alzheimer's disease: Can the inhibitors of MAGL and FAAH prove to be potential therapeutic targets against the cognitive impairment associated with Alzheimer's disease?PubMed 34217798 DOI 10.1016/j.brainresbull.2021.06.022
Potential of Fatty Acid Amide Hydrolase (FAAH), Monoacylglycerol Lipase (MAGL), and Diacylglycerol Lipase (DAGL) Enzymes as Targets for Obesity Treatment: A Narrative Review.PubMed 34959715 DOI 10.3390/ph14121316
Inhibition of endocannabinoid synthesis enzymes DAGL and NAPE-PLD transiently lowers body weight and alters glucose homeostasis during a high-fat diet challenge in mice.PubMed 41092478 DOI 10.1093/ejendo/lvaf212
Subcellular localization of NAPE-PLD and DAGL-α in the ventromedial nucleus of the hypothalamus by a preembedding immunogold method.PubMed 24346263 DOI 10.1007/s00418-013-1174-x
Microglial morphological/inflammatory phenotypes and endocannabinoid signaling in a preclinical model of periodontitis and depression.PubMed 39245706 DOI 10.1186/s12974-024-03213-5
Critical enzymes involved in endocannabinoid metabolism.PubMed 17346227 DOI 10.2174/092986607780090829
Structural properties and role of the endocannabinoid lipases ABHD6 and ABHD12 in lipid signalling and disease.PubMed 30564946 DOI 10.1007/s00726-018-2682-8
The serine hydrolases MAGL, ABHD6 and ABHD12 as guardians of 2-arachidonoylglycerol signalling through cannabinoid receptors.PubMed 21418147 DOI 10.1111/j.1748-1716.2011.02280.x
Deregulation of the endocannabinoid system and therapeutic potential of ABHD6 blockade in the cuprizone model of demyelination.PubMed 30075103 DOI 10.1016/j.bcp.2018.07.042
Biochemical and pharmacological characterization of human α/β-hydrolase domain containing 6 (ABHD6) and 12 (ABHD12).PubMed 22969151 DOI 10.1194/jlr.m030411
Endocannabinoids, blood pressure and the human heart.PubMed 18426501 DOI 10.1111/j.1365-2826.2008.01677.x
The potential role of cannabinoids in dermatology.PubMed 31599175 DOI 10.1080/09546634.2019.1675854
Cannabinoids and Their Receptors in Skin Diseases.PubMed 38003712 DOI 10.3390/ijms242216523
Endocannabinoid system and its modulation of brain, gut, joint and skin inflammation.PubMed 33909195 DOI 10.1007/s11033-021-06366-1
The endocannabinoid system of the skin. A potential approach for the treatment of skin disorders.PubMed 30138623 DOI 10.1016/j.bcp.2018.08.022
Sebaceous immunobiology - skin homeostasis, pathophysiology, coordination of innate immunity and inflammatory response and disease associations.PubMed 36439142 DOI 10.3389/fimmu.2022.1029818
The endocannabinoid system of the skin in health and disease: novel perspectives and therapeutic opportunities.PubMed 19608284 DOI 10.1016/j.tips.2009.05.004
Modulators of the endocannabinoid system influence skin barrier repair, epidermal proliferation, differentiation and inflammation in a mouse model.PubMed 31350927 DOI 10.1111/exd.14012
Cannabinergic ligands.PubMed 12505686 DOI 10.1016/s0009-3084(02
Assay of CB1 Receptor Binding.PubMed 27245890 DOI 10.1007/978-1-4939-3539-0_5
Allosteric Modulation: An Alternate Approach Targeting the Cannabinoid CB1 Receptor.PubMed 27879006 DOI 10.1002/med.21418
Endocannabinoids and Their Pharmacological Actions.PubMed 26408156 DOI 10.1007/978-3-319-20825-1_1
Cannabinoid receptor 1 ligands: Biased signaling mechanisms driving functionally selective drug discovery.PubMed 39828030 DOI 10.1016/j.pharmthera.2025.108795
Synthesis and Pharmacological Characterization of a Novel Cannabinoid Receptor 1 Antagonist.PubMed 40521518 DOI 10.1021/acsomega.4c11355
Cannabinoid-based therapy as a future for joint degeneration. Focus on the role of CB2 receptor in the arthritis progression and pain: an updated review.PubMed 34050525 DOI 10.1007/s43440-021-00270-y
The pharmacology of cannabinoid receptors and their ligands: an overview.PubMed 16570099 DOI 10.1038/sj.ijo.0803272
Latest advances in cannabinoid receptor agonists.PubMed 19939187 DOI 10.1517/13543770903436505
Therapeutic potential of cannabinoid receptor 2 in the treatment of diabetes mellitus and its complications.PubMed 31461639 DOI 10.1016/j.ejphar.2019.172628
The endocannabinoid system: physiology and pharmacology.PubMed 15550444 DOI 10.1093/alcalc/agh110
Restoration of CB1 receptor function in hippocampal GABAergic neurons rescues memory deficits in Huntington's disease models.PubMed 40855505 DOI 10.1186/s40035-025-00500-w
Astroglial type-1 cannabinoid receptor (CB1): A new player in the tripartite synapse.PubMed 25967266 DOI 10.1016/j.neuroscience.2015.05.002
Pharmacological inhibition of the CB1 cannabinoid receptor restores abnormal brain mitochondrial CB1 receptor expression and rescues bioenergetic and cognitive defects in a female mouse model of Rett syndrome.PubMed 39300547 DOI 10.1186/s13229-024-00617-1
Hippocampal Deletion of CB1 Receptor Impairs Social Memory and Leads to Age-Related Changes in the Hippocampus of Adult Mice.PubMed 36613469 DOI 10.3390/ijms24010026
Analysis of the endocannabinoid system by using CB1 cannabinoid receptor knockout mice.PubMed 16596773 DOI 10.1007/3-540-26573-2_4
Functional Selectivity at Cannabinoid Receptors.PubMed 28826535 DOI 10.1016/bs.apha.2017.03.005
Crystal Structure of the Human Cannabinoid Receptor CB2.PubMed 30639103 DOI 10.1016/j.cell.2018.12.011
CB2 cannabinoid receptor agonist selectively inhibits the mechanosensitivity of mucosal afferents in the guinea pig bladder.PubMed 33749323 DOI 10.1152/ajprenal.00065.2021
Structural basis of selective cannabinoid CB2 receptor activation.PubMed 36922494 DOI 10.1038/s41467-023-37112-9
Patent review of cannabinoid receptor type 2 (CB2R) modulators (2016-present).PubMed 38886185 DOI 10.1080/13543776.2024.2368745
Recent Advances on Type-2 Cannabinoid (CB2) Receptor Agonists and their Therapeutic Potential.PubMed 36028971 DOI 10.2174/0929867329666220825161603
Emerging roles of cannabinoid receptor CB2 receptor in the central nervous system: therapeutic target for CNS disorders.PubMed 39264450 DOI 10.1007/s00213-024-06683-w
Cannabinoid CB2 receptors modulate alcohol induced behavior, and neuro-immune dysregulation in mice.PubMed 37061199 DOI 10.1016/j.bbr.2023.114439
The cannabinoid CB2 receptor as a target for inflammation-dependent neurodegeneration.PubMed 18615177 DOI 10.2174/157015907780866884
CB1 and CB2 cannabinoid receptor antagonists prevent minocycline-induced neuroprotection following traumatic brain injury in mice.PubMed 23960212 DOI 10.1093/cercor/bht202
What we know and do not know about the cannabinoid receptor 2 (CB2).PubMed 24877594 DOI 10.1016/j.smim.2014.04.002
Molecular networks underlying cannabinoid signaling in skeletal muscle plasticity.PubMed 35862111 DOI 10.1002/jcp.30837
Is GPR55 an anandamide receptor?PubMed 19647110 DOI 10.1016/s0083-6729(09
The GPR55 ligand L-alpha-lysophosphatidylinositol promotes RhoA-dependent Ca2+ signaling and NFAT activation.PubMed 18757503 DOI 10.1096/fj.08-108670
The Endocannabinoid System of Animals.PubMed 31527410 DOI 10.3390/ani9090686
Cannabis and Endocannabinoid Signaling in Epilepsy.PubMed 26408165 DOI 10.1007/978-3-319-20825-1_10
Cannabinoids in Gynecological Diseases.PubMed 34676329 DOI 10.1159/000499164
Targeting GPR18: Structural modelling, ligand discovery, and therapeutic potential in neuroinflammatory disorders.PubMed 42114685 DOI 10.1016/j.bcp.2026.118038
An Update on Non-CB1, Non-CB2 Cannabinoid Related G-Protein-Coupled Receptors.PubMed 29098189 DOI 10.1089/can.2017.0036
GPR18 undergoes a high degree of constitutive trafficking but is unresponsive to N-Arachidonoyl Glycine.PubMed 27018161 DOI 10.7717/peerj.1835
Protective Effect of N-Arachidonoyl Glycine-GPR18 Signaling after Excitotoxical Lesion in Murine Organotypic Hippocampal Slice Cultures.PubMed 30871175 DOI 10.3390/ijms20061266
N-Acyl Amino Acids (Elmiric Acids): Endogenous Signaling Molecules with Therapeutic Potential.PubMed 29138268 DOI 10.1124/mol.117.110841
The elmiric acids: biologically active anandamide analogs.PubMed 18187165 DOI 10.1016/j.neuropharm.2007.11.011
Endocannabinoids and nutrition.PubMed 18426507 DOI 10.1111/j.1365-2826.2008.01687.x
Role of acylethanolamides in the gastrointestinal tract with special reference to food intake and energy balance.PubMed 19285259 DOI 10.1016/j.beem.2008.10.003
Regulation of GPR119 receptor activity with endocannabinoid-like lipids.PubMed 23074242 DOI 10.1152/ajpendo.00269.2012
Members of the endocannabinoid system are distinctly regulated in inflammatory bowel disease and colorectal cancer.PubMed 30787385 DOI 10.1038/s41598-019-38865-4
Fatty acid amide hydrolase (FAAH) and the endocannabinoid system in obesity: Mechanistic insights and pharmacological opportunities beyond incretin-based therapies.PubMed 42144898 DOI 10.1111/bph.70511
Oleoylethanolamide: A novel pharmaceutical agent in the management of obesity-an updated review.PubMed 30537148 DOI 10.1002/jcp.27913
Endocannabinoid signaling in microglia.PubMed 36222019 DOI 10.1002/glia.24281
The TRPV1 channel regulates glucose metabolism.PubMed 31408376 DOI 10.1152/ajpendo.00102.2019
Beyond Cannabis: Plants and the Endocannabinoid System.PubMed 27179600 DOI 10.1016/j.tips.2016.04.005
Transcriptomic signature, bioactivity and safety of a non-hepatotoxic analgesic generating AM404 in the midbrain PAG region.PubMed 38750093 DOI 10.1038/s41598-024-61791-z
Potential Future Pharmacological Treatment of Bladder Dysfunction.PubMed 26990140 DOI 10.1111/bcpt.12577
Role of endothelial TRPV4 channels in vascular actions of the endocannabinoid, 2-arachidonoylglycerol.PubMed 26294342 DOI 10.1111/bph.13312
Structure-affinity relationships and pharmacological characterization of new alkyl-resorcinol cannabinoid receptor ligands: Identification of a dual cannabinoid receptor/TRPA1 channel agonist.PubMed 25065940 DOI 10.1016/j.bmc.2014.07.006
TRPM8's Role in the Shift Between Opioid and Cannabinoid Pathways in Electroacupuncture for Inflammatory Pain in Mice.PubMed 39684707 DOI 10.3390/ijms252313000
Regulation of transient receptor potential channels of melastatin type 8 (TRPM8): effect of cAMP, cannabinoid CB(1) receptors and endovanilloids.PubMed 17428469 DOI 10.1016/j.yexcr.2007.01.008

Endocannabinoids has research behind it, but the bucket matters.

What the Endocannabinoids research is usually about

CB1

CB2

endocannabinoid enzyme activity or metabolic mechanisms

Safety, risk, adverse events, and formulation concerns

Endocannabinoids and endocannabinoid-like lipids

GPR18

Evidence buckets before the source table

Keep reading around this topic

Read safety context beside the research guide.

Endocannabinoids Evidence Review: the long-form source walk-through

Start with the research question

Where this page has the most source density

Bucket chapters: what the literature is circling

CB1

CB2

endocannabinoid enzyme activity or metabolic mechanisms

Safety, risk, adverse events, and formulation concerns

Endocannabinoids and endocannabinoid-like lipids

GPR18

GPR119

receptor, target, or pharmacology mechanisms

Human evidence, mechanisms, and safety are different lanes

What this does and does not mean

How to use the source table

Source-reading checklist for Endocannabinoids

Endocannabinoids source-by-source reading notes

Source-backed evidence table and references

Plain-Language Summary

Identity

Evidence Snapshot

Key Draft Sections

Evidence Relationships

Source-Backed Evidence Table

Related Pages

References